Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yungjin Pharmaceutical Co., Ltd. (003520:KRX), powered by AI.
Yungjin Pharmaceutical Co., Ltd. is currently trading at ₩1,271. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yungjin Pharmaceutical Co., Ltd. on Alpha Lenz.
Yungjin Pharmaceutical Co., Ltd.'s P/E ratio is -1021.1.
“Yungjin Pharmaceutical Co., Ltd. trades at a P/E of -1021.1 (undervalued) with modest ROE of -0.3%.”
Ask for details →Yungjin Pharmaceutical Co., Ltd. is a distinguished name in the pharmaceutical industry, primarily engaged in the research, development, and production of pharmaceutical products. The company focuses on delivering a wide array of medicinal solutions, including prescription drugs, over-the-counter medications, and health supplements. Its innovative approach in pharmaceutical formulations caters to various medical needs, encompassing fields such as cardiology, oncology, and infectious diseases. Yungjin Pharmaceutical Co., Ltd. plays a crucial role in the health sector by advancing medical technologies and improving patient care through quality and efficient medication. With a commitment to research and development, the company is pivotal in introducing cutting-edge therapeutic solutions, aiding healthcare practitioners and enhancing patient outcomes globally. The company’s contributions are significant in addressing public health challenges and promoting general wellness in the communities it serves.
“Yungjin Pharmaceutical Co., Ltd. trades at a P/E of -1021.1 (undervalued) with modest ROE of -0.3%.”
Ask for details →Yungjin Pharmaceutical Co., Ltd. (ticker: 003520) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 574 employees. Market cap is $232.5B.
The current price is ₩1,271 with a P/E ratio of -1,021.07x and P/B of 2.54x.
ROE is -0.25% and operating margin is 1.90%. Annual revenue is $254.3B.